Predictors of immunotherapeutic benefits in patients with advanced melanoma and other malignancies treated with immune checkpoint inhibitors utilizing ORIEN “real-world” data.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ahmad A. Tarhini, Aik Choon Tan, Mengyu Xie, Issam El Naqa, Payman Ghasemi Saghand, Donghai Dai, James Lin Chen, Aakrosh Ratan, Martin McCarter, John D. Carpten, Howard Colman, Alexandra Ikeguchi, Abhishek Tripathi, Igor Puzanov, Susanne M. Arnold, Michelle L. Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner
Institutions: Moffitt Cancer Center, University of Iowa, The Ohio State University, University of Virginia, University of Colorado Cancer Center, University of Southern California, University of Utah, Huntsman Cancer Institute, University of Oklahoma, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Roswell Park Comprehensive Cancer Center, University of Kentucky, University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286297416